» Articles » PMID: 23403317

A Reversion of an IL2RG Mutation in Combined Immunodeficiency Providing Competitive Advantage to the Majority of CD8+ T Cells

Overview
Journal Haematologica
Specialty Hematology
Date 2013 Feb 14
PMID 23403317
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the common gamma chain (γc, CD132, encoded by the IL2RG gene) can lead to B(+)T(-)NK(-) X-linked severe combined immunodeficiency, as a consequence of unresponsiveness to γc-cytokines such as interleukins-2, -7 and -15. Hypomorphic mutations in CD132 may cause combined immunodeficiencies with a variety of clinical presentations. We analyzed peripheral blood mononuclear cells of a 6-year-old boy with normal lymphocyte counts, who suffered from recurrent pneumonia and disseminated mollusca contagiosa. Since proliferative responses of T cells and NK cells to γc -cytokines were severely impaired, we performed IL2RG gene analysis, showing a heterozygous mutation in the presence of a single X-chromosome. Interestingly, an IL2RG reversion to normal predominated in both naïve and antigen-primed CD8(+) T cells and increased over time. Only the revertant CD8(+) T cells showed normal expression of CD132 and the various CD8(+) T cell populations had a different T-cell receptor repertoire. Finally, a fraction of γδ(+) T cells and differentiated CD4(+)CD27(-) effector-memory T cells carried the reversion, whereas NK or B cells were repeatedly negative. In conclusion, in a patient with a novel IL2RG mutation, gene-reverted CD8(+) T cells accumulated over time. Our data indicate that selective outgrowth of particular T-cell subsets may occur following reversion at the level of committed T progenitor cells.

Citing Articles

Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing.

Hou Y, Urena-Bailen G, Mohammadian Gol T, Gratz P, Gratz H, Roig-Merino A Genes (Basel). 2022; 13(12).

PMID: 36553615 PMC: 9777626. DOI: 10.3390/genes13122348.


Gene therapy for inborn errors of immunity: past, present and future.

Fischer A Nat Rev Immunol. 2022; 23(6):397-408.

PMID: 36434109 DOI: 10.1038/s41577-022-00800-6.


EBV-associated lymphoproliferative disorder in a patient with X-linked severe combined immunodeficiency with multiple reversions of an mutation in T cells.

Wada F, Kondo T, Nakamura M, Uno S, Fujimoto M, Miyamoto T EJHaem. 2022; 1(2):581-584.

PMID: 35845012 PMC: 9175913. DOI: 10.1002/jha2.119.


Somatic Reversion of a Novel Mutation Resulting in Atypical X-Linked Combined Immunodeficiency.

Hou Y, Gratz H, Urena-Bailen G, Gratz P, Schilbach-Stuckle K, Renno T Genes (Basel). 2022; 13(1).

PMID: 35052377 PMC: 8774591. DOI: 10.3390/genes13010035.


Reversion Mosaicism in Primary Immunodeficiency Diseases.

Miyazawa H, Wada T Front Immunol. 2021; 12:783022.

PMID: 34868061 PMC: 8635092. DOI: 10.3389/fimmu.2021.783022.


References
1.
Noguchi M, Yi H, Rosenblatt H, Filipovich A, Adelstein S, Modi W . Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993; 73(1):147-57. DOI: 10.1016/0092-8674(93)90167-o. View

2.
Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

3.
van Gisbergen K, Klarenbeek P, Kragten N, Unger P, Nieuwenhuis M, Wensveen F . The costimulatory molecule CD27 maintains clonally diverse CD8(+) T cell responses of low antigen affinity to protect against viral variants. Immunity. 2011; 35(1):97-108. DOI: 10.1016/j.immuni.2011.04.020. View

4.
Arredondo-Vega F, Santisteban I, Richard E, Bali P, Koleilat M, Loubser M . Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy. Blood. 2002; 99(3):1005-13. DOI: 10.1182/blood.v99.3.1005. View

5.
Kuijpers T, Bende R, Baars P, Grummels A, Derks I, Dolman K . CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2009; 120(1):214-22. PMC: 2798692. DOI: 10.1172/JCI40231. View